Translational research in breast cancer

被引：1

作者：

Masakazu Toi

Yuji Takebayashi

Louis W. Chow

机构：

[1] Metropolitan Komagome Hospital,Department of Surgery II

[2] Tokyo Metropolitan Cancer and Infectious Disease Centre,Division of Breast Surgery, Department of Surgery

[3] Fukushima Medical University,undefined

[4] University of Hong Kong Medical Centre,undefined

[5] Queen Mary Hospital,undefined

来源：

Breast Cancer | 2005年 / 12卷 / 2期

关键词：

Translational research; Breast cancer; Neoadjuvant chemotherapy; Trastuzumab; Hormone therapy;

D O I：

10.2325/jbcs.12.86

中图分类号：

学科分类号：

摘要：

Translational research (TR) involves both the development of novel diagnostics and novel therapeutics. These two major developmental areas are often associated with each other and these associations often bring new paradigms in the management of cancer patients. For example, the development of trastuzumab-based treatments has been conducted in harmony with the development of new methodologies to assess the expression of the Her-2 gene or protein, and from this, a therapeutic modality was established for breast cancer patients as a novel and individualized treatment system. TR covers a broad spectrum, from diagnosis to treatment, and it seems to act as a catalyst for developing novel paradigms. Therefore, it is crucial to conduct TR in clinical trials, in particular, prospective clinical trials. In this regard, TR can accelerate the development of new methodologies and increase trial efficiency. In this review, we describe the importance of TR, particularly that related to novel therapeutics.

引用

页码：86 / 90

页数：4

共 48 条

[1]

Hortobagyi GN(1998)Treatment of breast cancer N Engl J Med 339 974-984

[2]

Goldhirsch A(2001)Tamoxifen for early breast cancer Cochrane Database Syst Rev 1 CD000486-CD000486

[3]

Wood WC(2003)Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357-3365

[4]

Gelber RD(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792

[5]

Slamon DJ(1998)Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672-2685

[6]

Leyland-Jones B(2001)Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96-102

[7]

Shak S(2003)Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy Med Sci Monit 9 90-95

[8]

Fisher B(2003)Clinical trial methods to discover and validate predictive markers for treatment response in cancer Biotechnol Annu Rev 9 259-267

[9]

Bryant J(2004)Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Br J Cancer 90 2338-2343

[10]

Wolmark N(2003)Dannenberg AJ Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR J Biol Chem 278 37637-37647

← 1 2 3 4 5 →